Blood Clot Risk with Xeljanz
Xeljanz (tofacitinib), a JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and ankylosing spondylitis, carries a boxed warning for increased risk of blood clots, including deep vein thrombosis (DVT), pulmonary embolism (PE), and arterial thrombosis. This risk emerged from clinical trials and post-marketing data, leading to FDA updates in 2019 and beyond.[1][2]
Patients on Xeljanz, especially at higher 10 mg twice-daily doses or in combination with other clot-risk factors, face elevated incidence. Real-world rates show clots in about 0.3-1% of users annually, higher than placebo (0.1%) and rivals like Humira (0.2%). Risk rises with age over 50, smoking, heart disease history, or immobility.[3]
How Xeljanz Increases Clot Risk
Tofacitinib blocks JAK enzymes, reducing inflammation but also disrupting clot-regulating pathways like platelet aggregation and vascular repair. Trials like ORAL Surveillance (comparing Xeljanz 5/10 mg BID to TNF inhibitors in RA patients 50+ with cardiovascular risks) found:
- Major adverse cardiovascular events (MACE), including clots: 3.4% (5 mg) and 4.2% (10 mg) vs. 2.5% for TNF inhibitors.
- Venous thromboembolism (VTE): 1.7% overall for Xeljanz vs. 0.7% for comparators.
Higher doses amplify this; 10 mg BID showed 1.76x VTE risk vs. TNFs.[2][4]
Who Faces Highest Risk
- Dose-dependent: 10 mg BID (used short-term for ulcerative colitis) doubles clot odds vs. 5 mg BID.[2]
- Patient factors: Over 65, current/former smokers, cardiovascular disease, cancer history, or prior clots—ORAL trial excluded low-risk patients, highlighting vulnerability in high-risk groups.[3]
- Duration: Risks appear within months; long-term use (>1 year) sustains elevation.[4]
Comparison to Other RA Drugs
Xeljanz clots exceed biologics:
| Drug | VTE Rate (per 100 patient-years) | Notes |
|------|----------------------------------|-------|
| Xeljanz 5 mg BID | 0.38 | ORAL Surveillance[4] |
| Xeljanz 10 mg BID | 0.73 | Highest among JAKs[4] |
| Humira (adalimumab) | 0.16 | Lower across trials[3] |
| Rinvoq (upadacitinib) | 0.32 (15 mg) | Similar JAK profile[5] |
TNF inhibitors and IL-6 blockers like Olumiant show lower rates, prompting FDA preference for these in high-risk RA patients.[1]
What Doctors and FDA Recommend
Avoid Xeljanz as first-line in high-risk patients (age 50+, smokers, CV risks). Use lowest effective dose (5 mg BID). Monitor for leg swelling, chest pain, shortness of breath. Discontinue if clot suspected. European Medicines Agency restricts high-dose use.[1][6]
Patient reports on forums note clots within 3-6 months, often leg DVTs.[7]
Ongoing Studies and Updates
Post-ORAL data (2021-2023) confirm persistent risk; no new mitigations. Generic tofacitinib patents expire 2025-2030 (check DrugPatentWatch.com for details).[8] Biosimilars may enter, but warnings persist.
Sources
[1]: FDA Xeljanz Label
[2]: FDA Safety Communication 2019
[3]: NEJM ORAL Surveillance
[4]: Pfizer ORAL Data Summary
[5]: Rinvoq Label
[6]: EMA Tofacitinib Review
[7]: Patient forums (e.g., CreakyJoints, Drugs.com reviews)
[8]: DrugPatentWatch.com - Tofacitinib